Read + download the full collection of #ASGCTBreakthroughs24 abstracts ahead of our inaugural muscular dystrophy conference Nov. 19-20.
ASGCT members have collectively engaged in over two decades of the basic, translational, and clinical research that has led to the recent critical clinical advancements in the gene and cell therapy field. A key strategic priority of the Society is to support continued innovation by encouraging federal research funding for gene and cell therapy research. ASGCT will be further engaging with NIH Institutes and Centers to highlight research needs and funding gaps and to advocate for ways to address them. Policy positions have included support of the following:
Robust appropriations from Congress to the National Institutes of Health (NIH) for biomedical research in general.
Dedicated funding from Congress to the NIH specifically for gene and cell therapy research, such as through continued funding of the Regenerative Medicine Innovation Project.
Inclusion of gene and cell therapy research in the priorities of NIH Institutes and Centers in the awarding of research funding.
The Government Relations Committee provides oversight and input to ASGCT staff on Society efforts in support of research funding.
ASGCT is a member of the following alliances:
November 19-20, 2024 | Chicago, IL
© 2000-2024 All rights reserved. American Society of Gene & Cell Therapy.
Kentico CMS Development by Reason One | Powered by Kentico